β-Catenin Regulates the Expression of the Matrix Metalloproteinase-7 in Human Colorectal CancerThomas Brabletz, Thomas Kirchner|American Journal Of Pathology|1999Cited by 663
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trialSebastian Stintzing, Volker Heinemann, Dominik Paul Modest et al.|The Lancet Oncology|2016Cited by 417
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study groupDominik Paul Modest, Anke Reinacher‐Schick, Rainer Porschen et al.|Annals of Oncology|2016Cited by 344
Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFRVolker Heinemann, Andreas Jung, Sebastian Stintzing et al.|Cancer Treatment Reviews|2008Cited by 205
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialSebastian Stintzing, Volker Heinemann, Pratyaksha Wirapati et al.|Annals of Oncology|2019Cited by 194